1. JCO Precis Oncol. 2019 Sep 11;3:PO.19.00189. doi: 10.1200/PO.19.00189. 
eCollection 2019.

Emergence and Targeting of Acquired and Hereditary Resistance to Multikinase RET 
Inhibition in Patients With RET-Altered Cancer.

Wirth LJ(1), Kohno T(2), Udagawa H(3), Matsumoto S(3), Ishii G(3), Ebata K(4), 
Tuch BB(4), Zhu EY(4), Nguyen M(4), Smith S(4), Hanson LM(5), Burkard MR(5), 
Cable L(4), Blake JF(4), Condroski KR(3), Brandhuber BJ(3), Andrews S(3), 
Rothenberg SM(4), Goto K(3).

Author information:
(1)Massachusetts General Hospital Cancer Center, Boston, MA.
(2)National Cancer Research Institute, Tokyo, Japan.
(3)National Cancer Center Hospital East, Kashiwa, Japan.
(4)Loxo Oncology, Stamford, CT.
(5)Array BioPharma, Boulder, CO.

DOI: 10.1200/PO.19.00189
PMCID: PMC7446343
PMID: 32923848

Conflict of interest statement: The following represents disclosure information 
provided by authors of this manuscript. All relationships are considered 
compensated. Relationships are self-held unless noted. I = Immediate Family 
Member, Inst = My Institution. Relationships may not relate to the subject 
matter of this manuscript. For more information about ASCO's conflict of 
interest policy, please refer to www.asco.org/rwc or 
ascopubs.org/po/author-center.Lori J. WirthConsulting or Advisory Role: Merck, 
Loxo Oncology, Blueprint Medicines, Eisai, Amgen, Novartis, Ayala 
Pharmaceuticals, CUE Biopharma, Genentech, Iovance Biotherapeutics, Rakuten 
Medical Other Relationship: Iovance BiotherapeuticsTakashi KohnoConsulting or 
Advisory Role: Loxo Oncology Research Funding: Daiichi Sankyo, SysmexHibiki 
UdagawaHonoraria: AstraZeneca, Chugai Pharmaceutical, Bristol-Myers Squibb, Ono 
Pharmaceutical, MSD, Taiho Pharmaceutical, Amco, AbbVie, Boehringer Ingelheim, 
Daiichi Sankyo Consulting or Advisory Role: AbbVie, Boehringer Ingelheim 
Research Funding: MSD, AbbVie, Daiichi Sankyo, AmgenShingo MatsumotoHonoraria: 
Pfizer, Novartis, Chugai Pharma, AstraZeneca Research Funding: Chugai Pharma 
(Inst), Novartis (Inst), Lilly (Inst), Merck Serono (Inst), Merck Sharp & Dohme 
(Inst)Kevin EbataEmployment: Loxo Oncology Stock and Other Ownership Interests: 
Loxo Oncology Travel, Accommodations, Expenses: Loxo OncologyBrian B. 
TuchEmployment: Loxo Oncology Stock and Other Ownership Interests: Loxo Oncology 
Consulting or Advisory Role: Kezar Life Sciences Patents, Royalties, Other 
Intellectual Property: Biomarkers for NTRK inhibition; biomarkers for proteasome 
inhibitionEdward Y. ZhuEmployment: Loxo Oncology Stock and Other Ownership 
Interests: Loxo Oncology Travel, Accommodations, Expenses: Loxo OncologyMichele 
NguyenEmployment: Loxo Oncology Stock and Other Ownership Interests: Loxo 
Oncology Travel, Accommodations, Expenses: Loxo OncologySteve SmithConsulting or 
Advisory Role: Loxo Oncology, various Patents, Royalties, Other Intellectual 
Property: Various patents and applications Travel, Accommodations, Expenses: 
VariousLauren M. HansonEmployment: Array BioPharma Stock and Other Ownership 
Interests: Array BioPharma Research Funding: Array BioPharmaMichael R. 
BurkardEmployment: Array Biopharma, University of Colorado Hospital (I) Stock 
and Other Ownership Interests: Array BioPharma, Pfizer, Pfizer (I)James F. 
BlakeEmployment: Array BioPharma Stock and Other Ownership Interests: Array 
BioPharma Patents, Royalties, Other Intellectual Property: I am listed as a 
co-author on approximately 46 patents (Inst)Kevin R. CondroskiEmployment: Loxo 
Oncology Stock and Other Ownership Interests: Loxo Oncology Travel, 
Accommodations, Expenses: Loxo OncologyBarbara J. BrandhuberEmployment: Loxo 
Oncology Stock and Other Ownership Interests: Loxo Oncology, Array BioPharma 
Travel, Accommodations, Expenses: Loxo OncologySteve AndrewsEmployment: Loxo 
Oncology Leadership: Loxo Oncology Stock and Other Ownership Interests: Loxo 
Oncology Travel, Accommodations, Expenses: Loxo OncologyS. Michael 
RothenbergEmployment: Loxo Oncology Stock and Other Ownership Interests: Loxo 
Oncology Travel, Accommodations, Expenses: Loxo OncologyKoichi GotoHonoraria: 
Bristol-Myers Squibb, AstraZeneca, Pfizer, Chugai Pharmaceutical, Taiho 
Pharmaceutical, Ono Pharmaceutical, Novartis, Eli Lilly, Boehringer Ingelheim, 
Quintiles, Merck Serono, Life Technologies, MSD, AbbVie, Riken Genesis, Nippon 
Kayaku, Takeda Pharmaceuticals, Otsuka Pharmaceutical, SRL Diagnostics 
Consulting or Advisory Role: Otsuka Pharmaceutical Research Funding: MSD, 
AstraZeneca, Taiho Pharmaceutical, Chugai Pharmaceutical, Boehringer Ingelheim, 
Ono Pharmaceutical, Sumitomo Dainippon, Takeda Pharmaceuticals, Novartis, 
Daiichi Sankyo, Kyowa Hakko Kirin, Astellas Pharma, Eisai, Eli Lilly, Pfizer, 
Riken Genesis, Bristol-Myers Squibb, Merck Serono, Ignyta, Life Technologies, 
Research Triangle Institute d/b/a RTI Health Solutions, Janssen, Xcoo, Loxo 
Oncology No other potential conflicts of interest were reported.